Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas

Annals of Surgery

Volumn 231, Issue 3, 2000, Pages 380-386

  Schwarzbach, Matthias H M ^a   Dimitrakopoulou Strauss, Antonia ^b   Willeke, Frank ^a   Hinz, Ulf ^a   Strauss, Ludwig G ^b   Zhang, Yu Min ^b   Mechtersheimer, Gunhild ^a   Attigah, Nico ^a   Lehnert, Thomas ^a   Herfarth, Christian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER GRADING; CANCER SIZE; CLINICAL ARTICLE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; EVALUATION STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SARCOMA; SOFT TISSUE NEOPLASMS; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034054766     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200003000-00011     Document Type: Article

References (36)

1. Warburg O. The Metabolism of Tumors. New York: Smith; 1931.
2. Hawkins RA, Hoh CK, Dahlbom M, et al. PET cancer evaluations with FDG. J Nucl Med 1991; 32:1555-1558.
3. Som P, Atkins HL, Bandoypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21:670-675.
4. Barker FG 2nd, Chang SM, Valk PE, et al. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 1997; 79:115-126.
5. Flanagan FL, Dehdashti F, Ogunbiyi OA, et al. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998; 227:319-323.
6. Lai DT, Fulham M, Stephen MS, et al. The role of whole-body positron emission tomography with [18-F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996; 131:703-707.
7. Smith IC, Ogston KN, Whitford P, et al. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg 1998; 228:220-227.
8. Holder WD Jr, White RL Jr, Zuger JH, et al. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998; 227:764-771.
9. Enzinger FM, Weiss SW. Soft Tissue Tumors. 3d ed. St. Louis, MO: Mosby; 1995:17-87.
10. Hudson TM, Schakel M, Springfield DS. Limitations of computed tomography following excisional biopsy of soft tissue sarcomas. Skeletal Radiol 1985; 13:49-54.
11. Weekes RG, Berquist TH, McLeod RA, Zimmer WD. Magnetic resonance imaging of soft-tissue tumors: comparison with computed tomography. Magn Reson Imaging 1985; 3:345-352.
12. Reuther G, Mutschler W. Detection of local recurrent disease in musculoskeletal tumors: magnetic resonance imaging versus computed tomography. Skeletal Radiol 1990; 19:85-90.
13. Pino G, Conzi GF, Murolo C, et al. Sonographic evaluation of local recurrences of soft tissue sarcomas. J Ultrasound Med 1993; 12:23-26.
14. Weiss SW. WHO Histological Typing of Soft Tissue Tumors. 2d ed. Berlin: Springer Verlag; 1994:1-86.
15. Hermanek P, Sobin LH, eds. UICC TNM Classification of Malignant Tumors. 4th ed. rev 2. Berlin: Springer; 1992:92-95.
16. Toorongian SA, Mulholland GK, Jewett DM, et al. Routine production of 2-deoxy-2-[18F]fluoro-D-glucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin. Nucl Med Biol 1990; 3:273-279.
17. Kontaxakis G, Tzanakos GS, Strauss LG, et al. Characteristics of the local convergence behavior of the iterative ML-EM image reconstruction algorithms. J Nucl Med 1997; 38:202-204.
18. Schmidlin P, Kübler WK, Doll J. Image processing in whole-body positron emission tomography. In: Schmidt HAE, Csernay L, eds. Nuclearmedizin. Stuttgart: Schattauer; 1987:84-87.
19. Burger C, Buck A. Requirements and implementation of a flexible kinetic modeling tool. J Nucl Med 1997; 38:1818-1823.
20. Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991; 32:1508-1512.
21. Griffeth LK, Dehdashti F, McGuire AH, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology 1992; 182:185-194.
22. Eary JF, Conrad EU, Bruckner JD, et al. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998; 4:1215-1220.
23. Sokoloff L, Reivich M, Kennedy C, et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28:897-916.
24. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metabol 1985; 5:584-590.
25. Lodge MA, Lucas JD, Marsden PK, et al. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26:22-30.
26. Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996; 37: 257-261.
27. Strauss LG. Fluorine-18 deoxyglucose and false positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996; 23:1409-1415.
28. Meyer MA. Diffusely increased colonie F-18 FDG uptake in acute enterocolitis. Clin Nucl Med 1995; 20:434-435.
29. Sasaki M, Ichiya Y, Kuwabara Y, et al. Ringlike uptake of [18F]FDG in brain abscess: a PET study. J Comput Assist Tomogr 1990; 14: 486-487.
30. Schmall B, Conti PS, Bigler RE, et al. Synthesis and quality assurance of [11C] alpha-aminoisobutyric acid (AIB), a potential radiotracer for imaging and amino acid transport studies in normal and malignant tissues. Int J Nucl Med Biol 1984; 11:209-214.
31. Schwarzbach M, Willeke F, Dimitrakopoulou-Strauss A, et al. Functional imaging and detection of local recurrence in soft tissue sarcomas by positron emission tomography. Anticancer Res 1999; 19:1343-1350.
32. Schwarzbach M, Lehnert T, Willeke F, et al. The results of isolated hyperthermic limb perfusion in a multimodality therapy concept for soft-tissue sarcoma. Chirurg 1996; 67:1237-1243.
33. Willeke F, Eble MJ, Lehnert T, et al. The application of intraoperative radiotherapy in the surgical treatment of retroperitoneal soft tissue sarcoma. Chirurg 1995; 66:899-904.
34. Arbeit JM, Hilaris BS, Brennan MF. Wound complications in the multimodality treatment of extremity and superficial truncal sarcomas. J Clin Oncol 1987; 5:480-488.
35. Kole AC, Nieweg OE, van Ginkel RJ, et al. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]Fluorodeoxyglucose. Ann Surg Oncol 1997; 4:57-63.
36. Lucas JD, O'Doherthy MJ, Wong JC, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br 1998; 80:441-447.